Impact of Acetic Acid Chromoendoscopy on Neoplasia Detection in Barrett's EsophagusAcetic acid chromoendoscopy does not improve neoplasia detection in Barrett's

The clinical management of Barrett's esophagus (BE) relies heavily on endoscopic surveillance to identify and manage precancerous changes. A significant point of debate in gastroenterology is whether the addition of acetic acid chromoendoscopy (AAC) provides a diagnostic advantage over standard white-light endoscopy. This large-scale, stepped wedge cluster randomized controlled trial was designed to provide high-level evidence regarding the efficacy of AAC in detecting low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma in a real-world clinical setting.

The study enrolled a substantial cohort of 2,267 patients undergoing surveillance for Barrett's esophagus across 18 Dutch community hospitals. To ensure the integrity of the data, patients with known or previously treated dysplasia were excluded from the analysis. This population size provides significant statistical power to evaluate the primary outcome: the detection rate of neoplasia. The study design allowed for a robust comparison between standard surveillance and the integration of AAC into the clinical workflow.

Primary results indicated that the neoplasia detection rate was 7.4% in the group utilizing AAC compared to 7.1% in the group without it. The calculated odds ratio was 0.97, with a 95% confidence interval ranging from 0.65 to 1.44. These findings suggest that the inclusion of acetic acid does not significantly increase the identification of clinically relevant neoplasia in patients undergoing routine surveillance. The absolute numbers (50/679 vs. 113/1588) confirm that the difference was not statistically significant.

Interestingly, the study did observe a significant increase in the detection of suspected lesions when AAC was employed. The rate of suspected lesions was 14.0% with AAC versus 6.4% without it (P<0.001). While this suggests that acetic acid may highlight suspicious areas or mucosal changes, these findings did not translate into a higher rate of confirmed neoplasia in targeted biopsies. The targeted neoplasia detection rate was 2.1% with AAC and 1.8% without, yielding an odds ratio of 1.05 (95% CI: 0.49 to 2.24).

From a clinical perspective, these results suggest that while AAC may increase the number of suspicious areas identified during endoscopy, it does not improve the diagnostic yield for actual neoplasia in the context of routine surveillance. Clinicians may find that while AAC provides a visual aid, it does not fundamentally change the primary outcome of neoplasia detection in this specific patient population. The lack of a significant difference in the primary endpoint suggests that standard white-light endoscopy remains a robust tool for surveillance. In conclusion, the evidence from this trial indicates that the integration of acetic acid chromoendoscopy into the surveillance protocol for Barrett's esophagus does not significantly improve the detection of low-grade or high-grade dysplasia or adenocarcinoma. While it may increase the identification of suspicious lesions, the clinical impact on the final diagnosis of neoplasia remains negligible. These findings may influence the decision-making process regarding the standard of care and the necessity of additional reagents in routine endoscopic surveillance programs.